EARLIER: Exact Sciences Publish Results of DeeP-C Study in NEJM
Exact Sciences Corp. (Nasdaq: EXAS) today announced that results from its DeeP-C pivotal clinical study have been published online in the New England Journal of Medicine. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal's April 3, 2014 print issue.
Tanya Quint loads an instrument at Exact Sciences' headquarters in Madison, Wis. (Photo: Business Wi ...
Tanya Quint loads an instrument at Exact Sciences' headquarters in Madison, Wis. (Photo: Business Wire)
The 10,000-patient DeeP-C study was designed to determine the performance characteristics of Exact Sciences' multi-target stool DNA-based screening test, Cologuard ®, for colorectal cancer and to compare that performance to the fecal immunochemical test (FIT), a commonly used non-invasive colorectal cancer screening test. The DeeP-C study took place at 90 centers throughout the U.S. and Canada.
The DeeP-C data published in the NEJM elaborate on top-line data Exact Sciences announced in April of 2013. Data published today include:
* Sensitivity of Cologuard in detecting patients with colorectal cancer was 92% versus 74% for FIT; * Sensitivity in detecting patients with colorectal cancers in Stages I-III —those determined by the American Joint Committee on Cancer to be associated with an increased rate of being cured—was 93% for Cologuard versus 73 % for FIT; * Sensitivity for patients with advanced pre-cancerous lesions was 42% for Cologuard versus 24% for FIT; * Cologuard detected 69% of patients with polyps with high-grade dysplasia versus 46% for FIT; * Cologuard achieved a specificity of 87% versus FIT specificity of 95%.
Colorectal cancer is often considered the most preventable, yet least prevented cancer. One out of 3 adults age 50 and older has not been screened as recommended and, as a result, colorectal cancer remains the second-leading cancer killer in the United States. Colorectal cancer is highly treatable if found early, making the detection of pre-cancerous polyps paramount.
“We know that colorectal cancer can be prevented and can be highly treatable if found early through screening,” said lead author Thomas F. Imperiale M.D., of the Indiana University School of Medicine, Regenstrief Institute Inc., the IU Simon Cancer Center, and the Roudebush VA Medical Center in Indianapolis. “Sensitivity is the most important characteristic for screening tests because the primary role of such testing is to rule out diseases such as cancer. In our clinical study, the data show that Cologuard, the multi-target stool-based DNA test, is highly sensitive in detecting colorectal cancer and higher risk pre-cancerous polyps in a large, diverse average-risk patient population and has the potential to be an important screening tool.”
“We are very pleased with the data published today in the New England Journal of Medicine,” said Kevin T. Conroy, president and chief executive of Exact Sciences. “We believe Cologuard could be an important tool in the early detection of colorectal cancer. This is an important milestone for Exact Sciences and Cologuard.”
The Exact Sciences Cologuard screening test is an investigational device currently under review by the U.S. Food and Drug Administration (FDA) and is not available for sale in the United States. The FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science's PMA application for Cologuard on March 27, 2014.
New England Journal of Medicine Publication Webcast & Conference Call
Company management will host a webcast and conference call on Wednesday, March 19, 2014, at 11 a.m. ET to discuss the DeeP-C clinical trial data published today in the New England Journal of Medicine. The webcast will be available at www.exactsciences.com. Domestic callers should dial 877-212-6082 and international callers should dial 707-287-9332. An archive of the webcast and a replay of the conference call will be available at www.exactsciences.com or by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the conference call and replay is 16207488. The conference call, webcast and replay are open to all interested parties.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.